» Articles » PMID: 34001619

HIV Envelope Tail Truncation Confers Resistance to SERINC5 Restriction

Overview
Specialty Science
Date 2021 May 18
PMID 34001619
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

SERINC5 is a potent lentiviral restriction factor that gets incorporated into nascent virions and inhibits viral fusion and infectivity. The envelope glycoprotein (Env) is a key determinant for SERINC restriction, but many aspects of this relationship remain incompletely understood, and the mechanism of SERINC5 restriction remains unresolved. Here, we have used mutants of HIV-1 and HIV-2 to show that truncation of the Env cytoplasmic tail (ΔCT) confers complete resistance of both viruses to SERINC5 and SERINC3 restriction. Critically, fusion of HIV-1 ΔCT virus was not inhibited by SERINC5 incorporation into virions, providing a mechanism to explain how EnvCT truncation allows escape from restriction. Neutralization and inhibitor assays showed ΔCT viruses have an altered Env conformation and fusion kinetics, suggesting that EnvCT truncation dysregulates the processivity of entry, in turn allowing Env to escape targeting by SERINC5. Furthermore, HIV-1 and HIV-2 ΔCT viruses were also resistant to IFITMs, another entry-targeting family of restriction factors. Notably, while the EnvCT is essential for Env incorporation into HIV-1 virions and spreading infection in T cells, HIV-2 does not require the EnvCT. Here, we reveal a mechanism by which human lentiviruses can evade two potent Env-targeting restriction factors but show key differences in the capacity of HIV-1 and HIV-2 to exploit this. Taken together, this study provides insights into the interplay between HIV and entry-targeting restriction factors, revealing viral plasticity toward mechanisms of escape and a key role for the long lentiviral EnvCT in regulating these processes.

Citing Articles

SERINC5 counters retroviruses and non-retroviruses.

Yu J, Liu C, Qu X, Gao X, Liu Y Front Cell Infect Microbiol. 2025; 14:1516806.

PMID: 39902183 PMC: 11788155. DOI: 10.3389/fcimb.2024.1516806.


Disruption of Transmembrane Phosphatidylserine Asymmetry by HIV-1 Incorporated SERINC5 Is Not Responsible for Virus Restriction.

Raghunath G, Abbott E, Marin M, Wu H, Reyes Ballista J, Brindley M Biomolecules. 2024; 14(5).

PMID: 38785977 PMC: 11118262. DOI: 10.3390/biom14050570.


Beyond Impairment of Virion Infectivity: New Activities of the Anti-HIV Host Cell Factor SERINC5.

Sid Ahmed S, Bajak K, Fackler O Viruses. 2024; 16(2).

PMID: 38400059 PMC: 10892966. DOI: 10.3390/v16020284.


Role of Viral Envelope Proteins in Determining Susceptibility of Viruses to IFITM Proteins.

Marceau T, Braibant M Viruses. 2024; 16(2).

PMID: 38400030 PMC: 10892237. DOI: 10.3390/v16020254.


Antiviral factors and their counteraction by HIV-1: many uncovered and more to be discovered.

Kmiec D, Kirchhoff F J Mol Cell Biol. 2024; 16(2).

PMID: 38318650 PMC: 11334937. DOI: 10.1093/jmcb/mjae005.


References
1.
White E, Wu F, Chertova E, Bess J, Roser J, Lifson J . Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions. J Virol. 2017; 92(3). PMC: 5774881. DOI: 10.1128/JVI.01688-17. View

2.
Lu J, Pan Q, Rong L, He W, Liu S, Liang C . The IFITM proteins inhibit HIV-1 infection. J Virol. 2010; 85(5):2126-37. PMC: 3067758. DOI: 10.1128/JVI.01531-10. View

3.
Wu W, Grotefend C, Tsai M, Wang Y, Radic V, Eoh H . Δ20 IFITM2 differentially restricts X4 and R5 HIV-1. Proc Natl Acad Sci U S A. 2017; 114(27):7112-7117. PMC: 5502592. DOI: 10.1073/pnas.1619640114. View

4.
Vzorov A, Gernert K, Compans R . Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity. Virology. 2005; 332(1):89-101. DOI: 10.1016/j.virol.2004.10.044. View

5.
Nieto-Garai J, Arboleya A, Otaegi S, Chojnacki J, Casas J, Fabrias G . Cholesterol in the Viral Membrane is a Molecular Switch Governing HIV-1 Env Clustering. Adv Sci (Weinh). 2021; 8(3):2003468. PMC: 7856888. DOI: 10.1002/advs.202003468. View